Amgen Inc.

AMGN

Industry

Unknown

Exchange

NMS

Market Cap

N/A

Company Overview

Amgen generates revenue by discovering, developing, manufacturing, and commercializing innovative human therapeutics for serious illnesses. The company holds a leading market position in several therapeutic areas, including inflammation, oncology, and bone health. Its core competitive advantage stems from its deep scientific expertise in biologics, a robust intellectual property portfolio protecting its blockbuster drugs, and complex manufacturing capabilities.

Revenue Structure

Amgen's revenue is almost entirely derived from the sale of its proprietary human therapeutic products across various disease states. Top-selling products include Enbrel (inflammation), Prolia/Xgeva (bone health), Otezla (psoriasis/psoriatic arthritis), and Repatha (cardiovascular disease). Biosimilar products also contribute to revenue, though a smaller portion compared to its branded portfolio.

Key Risks

1Exposure to significant revenue erosion from biosimilar competition following patent expiries for key blockbuster drugs, particularly Enbrel.

2Failure of late-stage clinical trials or delays in regulatory approval for pipeline assets, impacting future growth prospects.

3Increasing pricing pressure and rebate demands from governments, private payers, and pharmacy benefit managers, constraining profitability and market access for its innovative drugs.

Key Points

Amgen represents a compelling investment due to its robust and diversified portfolio of biologics, a strong pipeline aimed at addressing unmet medical needs, and a proven track record of R&D innovation. Its ability to generate significant free cash flow and strategic capital allocation supports long-term shareholder value despite industry headwinds.

Get the full experience in the app

Favorites, stock comparison, PDF export, and community voting are available in the app.

View full analysis in TickerNote →

English·한국어